Evidence map›Paper›PMID 39590560›Full record

ArticleJournal of personalized medicine2024

Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning.

Kaiyuan Gong, Baptiste Magnier, Salomé L'hostis, Fanny Borrely, Sébastien Le Bon, Nadine Houede, Adel Mamou, Laurent Maimoun, Pierre Olivier Kotzki, Vincent Boudousq

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Future of radiotheranostics.BMJ oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kaiyuan GongDepartment of Computer Science & Artificial Intelligence, IMT Mines Ales, 30100 Ales, France.
Baptiste MagnierService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.ORCID 0000-0003-3458-0552
Salomé L'hostisFaculty of Medicine, Université de Montpellier, Nimes Caremeau Campus, 34295 Nîmes, France.
Fanny BorrelyService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.
Sébastien Le BonService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.
Nadine HouedeInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298 Montpellier, France.
Adel MamouService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.ORCID 0000-0002-1709-9233
Laurent MaimounService de Médecine Nucléaire, Hôpital Lapeyronie, CHU Montpellier, 34295 Montpellier, France.ORCID 0000-0002-1727-1048
Pierre Olivier KotzkiService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.
Vincent BoudousqService de Médecine Nucléaire, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, 34295 Nîmes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesRadioligandtherapy (RLT) with [177Lu]Lu-PSMA has been newly introduced as a routine treatment for metastatic castration-resistant prostate cancer (mCRPC). However, not all patients can tolerate the entire therapeutic sequence, and in some cases, the treatment may prove ineffective. In real-world conditions, the aim is to distinguish between patients who fully benefit from treatment (those who respond effectively and tolerate the entire therapeutic sequence) and those who do not respond or cannot tolerate the entire sequence. This study explores predictive factors to distinguish between fully beneficial RLT treatment patients (FBTP) and not fully beneficial RLT treatment patients (NFBTP). The objective was to enhance the understanding of predictive factors influencing RLT effectiveness and to highlight the significance of machine learning in optimizing patient selection for treatment planning.

methodsData from 25 mCRPC patients, categorized as FBTP (11) or NFBTP (14) to RLT, were analyzed. The dataset included clinical, imaging, and biological parameters. Data analysis techniques, including exploratory data analysis and feature engineering, were used to develop machine learning models for predicting patient outcomes.

resultsImaging data analysis revealed statistically significant differences in the renal uptake intensity of Choline between the two groups. A discordance of FDG+ and PSMA- was identified as a potential indicator of NFBTP. The integration of biological data enhanced the model's predictive capability, achieving an accuracy of 0.92, a sensitivity of 0.96, and a precision of 0.96. Adding blood parameters like neutrophils, leukocytes, and alkaline phosphatase greatly increased prediction accuracy.

conclusionsThis study emphasizes the significance of an integrated approach that merges imaging and biological data, thereby augmenting the predictive accuracy of patient outcomes in RLT with [177Lu]Lu-PSMA. In particular, including Choline PET among the imaging parameters provides unique insights into the predictive factors affecting RLT efficacy. This approach not only deepens the understanding of predictive factors but also underscores the utility of machine learning in refining the patient selection process for optimized treatment planning.

Indexed as

CholineFDG (fluorodeoxyglucose)Lu-177machine learning (ML)prostate cancer (PC)prostate specific membrane antigen (PSMA)radioligand therapy (RLT)response prediction

Identifiers

PMID39590560
PMCPMC11595926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.